<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4455">
  <stage>Registered</stage>
  <submitdate>25/10/2012</submitdate>
  <approvaldate>25/10/2012</approvaldate>
  <nctid>NCT01728805</nctid>
  <trial_identification>
    <studytitle>Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL</studytitle>
    <scientifictitle>Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>0761-010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cutaneous T-Cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - KW-0761
Treatment: drugs - Vorinostat

Experimental: KW-0761 - anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)

Active Comparator: Vorinostat - vorinostat 400 mg once daily


Other interventions: KW-0761
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression

Treatment: drugs: Vorinostat


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pruritis Evaluation</outcome>
      <timepoint>up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate</outcome>
      <timepoint>at the end of cycle 1 (26-28 days), and then every other cycle in Year 1 (cycle 3, 5, 7, 9, 11, 13), and every 16 weeks (cycle 17, 21, etc.) in Year 2 and beyond until progression up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Assessments</outcome>
      <timepoint>up to 36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and female subjects = 18 years of age at the time of enrollment, except in Japan
             where subjects must be = 20 years of age at the time of enrollment

          -  Histologically confirmed diagnosis of mycosis fungoides (MF) or Sezary Syndrome (SS)

          -  Stage IB, II-A, II-B, III and IV

          -  Subjects who have failed at least one prior course of systemic therapy. Psoralen plus
             ultraviolet light therapy (PUVA) is not considered to be a systemic therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of = 1 at study
             entry

          -  Resolution of all clinically significant toxic effects of prior cancer therapy to
             grade =1 by the National Cancer Institute Common Terminology Criteria for Adverse
             Events, version 4.0 (NCI-CTCAE, v.4.0)

          -  Adequate hematological, renal and hepatic function

          -  Subjects previously treated with anti-CD4 antibody or alemtuzumab are eligible
             provided their CD4+ cell counts are = 200/mm3

          -  Subjects with mycosis fungoides (MF) and a known history of non-complicated
             staphylococcus infection/colonization are eligible provided they continue to receive
             stable doses of prophylactic antibiotics

          -  Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7
             days of receiving study medication

          -  WOCBP and male subjects as well as their female partners of childbearing potential
             must agree to use effective contraception throughout the study and for 6 months after
             the last dose of KW-0761</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment with KW-0761 or vorinostat.

          -  Large cell transformation. However, subjects with a history of LCT but without current
             aggressive disease and no current evidence of LCT on pathology in skin and lymph nodes
             would be eligible.

          -  Diagnosed with a malignancy in the past two years. However, subjects with non-melanoma
             skin cancers, melanoma in situ, localized cancer of the prostate with current PSA of
             &lt;0.1 ng/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular
             carcinoma in situ of the breast within the past two years may enroll as long as there
             is no current evidence of disease.

          -  Clinical evidence of central nervous system (CNS) metastasis.

          -  Psychiatric illness, disability or social situation that would compromise the
             subject's safety or ability to provide consent, or limit compliance with study
             requirements.

          -  Significant uncontrolled intercurrent illness

          -  Known or tests positive for human immunodeficiency virus (HIV), human T-cell leukemia
             virus (HTLV-1), hepatitis B or hepatitis C.

          -  Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who started
             taking medication at least 30 days prior to study entry, and have no active signs of
             active infection, and whose last active infection was more than 6 months ago, may
             enter the study, and should continue to take the prescribed medication for the
             duration of the study.

          -  Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.

          -  Known active autoimmune disease will be excluded. (For example, Grave's disease;
             systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease; psoriasis).

          -  Is pregnant (confirmed by beta human chorionic gonadotrophin [ÃŸ-HCG]) or lactating.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>372</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Parkville Cancer Clinical Trials Unit - Melbourne</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre-Benite Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Turin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kagoshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kochi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Mie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Kyowa Hakko Kirin Pharma, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the progression free survival of KW-0761 versus
      vorinostat for subjects with relapsed or refractory CTCL.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01728805</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dmitri O. Grebennik, MD</name>
      <address>Kyowa Hakko Kirin Pharma, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>